0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV468.18%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cyclacel Pharmaceuticals Stock Discussion
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals announced preclinical data for fadraciclib, a CDK2/9 inhibitor, demonstrating efficacy in metastatic colorectal cancer (CRC) models. Presented at the 2024 ASCO Annual Meeting, the study showed that fadraciclib significantly inhibited tumor growth, induced apoptosis, and triggered anaphase catastrophe in CRC patie...
📊⚡️📊
👉 GHOST NET - DEMON TRAP - GAI WIX 👈👉 BUYERS MUST SELL ALL AND DELETE NOW👈. 👎THEY BLOCK SHORT + (BID & ASK TOO FAR & UNDER $1 DELETE ), THEY ONLY TRAP STUPID INVESTORS BILLION OF DOLLARS A DAY 🗡👊💣👹💰
(PIK - LPA - DHAC - SMFL - SMMT - SRDX - VSTM - SMR - UVXY - AVTX - BTTR - DXYZ - GNLX - CZOO - MRUS - OKLO - AKAN - SWIN - IGMS - ARRY - MARA - CTNT - GTBP - EDBL - MTC - CAR - ARM - CVNA - SITM - NSP - POWL - AWIN - GME - BIG - BMTX - DXYZ - DOGZ - HOLO - KOSS...
No comment yet